IMPROVING PAEDIATRIC TB CARE IN TAJIKISTAN

November 2013

Ministry of Health Tajikistan
### CONTENT

**Executive Summary** ........................................................................................................... 4

1. Introduction ....................................................................................................................... 5

1.1 The global burden of childhood TB .................................................................................. 5

1.1.1 Growing numbers of drug-resistant TB ................................................................. 5

1.1.2 The challenge of diagnosing and treating childhood TB ....................................... 5

1.2 TB in Central Asia .......................................................................................................... 5

1.2.1 Political commitment to tackle TB in Tajikistan .................................................. 5

1.3 Paediatric TB Care in Central Asia

1.3.1 The family TB care programme ............................................................................... 6

1.3.2 Programme activities ............................................................................................. 6

1.3.3 A new paediatric TB guideline ................................................................................ 6

2. Early and appropriate diagnosis ....................................................................................... 7

2.1 New diagnostic tools: sputum induction and GeneXpert

2.1.1 Sputum induction .................................................................................................... 7

2.1.2 Rapid drug sensitivity testing with GeneXpert ....................................................... 7

2.2 Determining the drug resistance pattern through contact history ................................ 7

2.3 Scaling up active case finding ...................................................................................... 8

2.3.1 Growth assessment .................................................................................................. 9

3. Early treatment – comprehensive clinical management .................................................. 10

3.1 Paediatric drug compounding ...................................................................................... 10

3.2 Side effect monitoring & management .......................................................................... 10

3.3 TB/HIV co-morbidity .................................................................................................... 10

4. Supporting the child's development – adherence and family support .............................. 11

4.1 Psycho-social adherence support for children and their families ................................. 11

4.2 Need for education – return to school and therapeutic play programme .................... 12

4.3 Relieving children of prolonged hospitalization .......................................................... 12

5. Conclusions and recommendations ................................................................................. 13

References ........................................................................................................................... 14

List of abbreviations ............................................................................................................. 14
EXECUTIVE SUMMARY

Context

Children as the most vulnerable patient group have been neglected for too long in tuberculosis (TB) treatment globally. Estimates for paediatric TB indicate it accounts for 10–15% of all tuberculosis cases in the 22 highest-burden countries and worldwide kills at least 130,000 children each year. Furthermore the numbers of children infected with drug-resistant (DR) forms of TB are rising. The primary reasons for this serious neglect are that both diagnosis and treatment of TB in children are particularly difficult as appropriate diagnostic tools for children are lacking and no paediatric drug formulations are commercially available. Furthermore adherence to a long and burdensome TB treatment, especially in the case of drug-resistant TB, is strenuous for the child and the family.

The paediatric TB care programme

To demonstrate the provision of comprehensive TB care for children is feasible and that TB and especially DR-TB can be successfully diagnosed and ultimately cured, the Tajik Ministry of Health (MoH) and Médecins Sans Frontières (MSF) began a comprehensive paediatric TB care programme in 2011.

Rationale and intention of the report

This report outlines the comprehensive model of paediatric TB care and presents the project experience in Tajikistan. Based on this experience it draws some conclusions and proposes some recommendations for scaling up paediatric TB care in the Central Asian and Eastern European region. It is intended to share experiences and lessons learned, highlight shortfalls and signpost opportunities to improve paediatric TB care and fully include children in National TB Programmes.

Lessons from the paediatric TB programme so far indicate that:

• To treat childhood TB effectively, a comprehensive treatment model is needed that includes the treatment of both DR and drug-sensitive (DS) TB and considers the entire family.
• Childhood TB needs to be diagnosed appropriately as early as possible, applying new diagnostic tools such as sputum induction, a rapid drug sensitivity test (DST) with GeneXpert as well as contact tracing.
• Early and comprehensive treatment needs to be provided that includes the compounding of paediatric drug formulations, systematic monitoring of side effects and their effective management, nutritional support and management of co-morbidities.
• The child and family need support to adhere to treatment and to minimise the negative impact that TB as a long term disease can have on a child’s development. This includes psycho-social adherence support, a return to school as soon as a child is sputum negative, a shortening of the hospitalization phase and preferably ambulatory care.

Together MoH, MSF and TB partners in Tajikistan will continue to search for and develop better approaches to diagnose and treat TB in children.
1. INTRODUCTION

1.1 The global burden of childhood TB

Tuberculosis in children is a global problem that has been neglected for too long. Where the disease is endemic, tuberculosis is a major but often unrecognized cause of disease and death among children. In 2011 there were an estimated 8.7 million incident cases of TB worldwide, of which 0.5 million were children, around 6% of the total number of worldwide incident cases. Estimates for paediatric TB indicate it accounts for 10–15% of all tuberculosis cases in the 22 highest-burden countries and worldwide kills at least 130,000 children each year. Clearly the number of paediatric cases is noteworthy and there is a pressing need to ensure children receive the special diagnostics and care required.

Despite these estimated figures, it can be assumed that paediatric TB numbers have so far been underreported and underestimated. Cases of childhood TB are not reported separately by all countries and in 2012, the World Health Organisation (WHO) included estimates of numbers of TB cases and deaths among children in the Global TB Report for the first time.

1.1.1 Growing numbers of drug-resistant TB

This picture is worryingly reflected for multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB. In 2008, 3.6% of incident tuberculosis cases globally were MDR or XDR-TB, suggesting there would have been a similar burden of drug-resistant TB among children. The numbers of children infected with drug-resistant forms of TB are rising.

1.1.2 The challenge of diagnosing and treating childhood TB

Case detection rates are low, not least due to the difficulties of diagnosing TB in children. One reason why TB in children is often under-diagnosed and why this vulnerable group has been neglected so far is that the diagnosis is more difficult than in adults. Children produce less sputum, often do not have large bacillary loads and the rate for extrapulmonary TB is higher than in adults. Therefore sometimes it is not feasible to confirm the diagnosis of TB with micro-biological proof. Treatment is challenging since no paediatric drug formulations are currently commercially available and with a long and burdensome disease, especially in the case of DR-TB when treatment can take up to two years, adherence to treatment is arduous for patients and their families.

Added to this, the consequences of a lengthy, debilitating illness can have a severe impact on the child’s development and so undoubtedly now is the time to ensure that paediatric TB management receives the attention it deserves. As paediatric TB is usually acquired from an infectious adult contact, the epidemiology of childhood TB reflects the success or failure of a TB programme.

1.2 TB in Central Asia

TB is a serious public health threat in the Central Asian region. WHO estimates of the general TB burden in the region for 2012 put the disease prevalence at a range from 99 to 217 per 100,000 population. The reported incidence rate ranges from 75 to 141 new cases per 100,000 population in 2012.

The Global TB report 2013 puts the case detection rate in the region for TB in the whole population at 66–81%. Unfortunately, children were not included in TB reports globally prior to 2012. In the absence of this data it is impossible to know the case detection rate for children, which may be considerably lower given the challenges with diagnosing paediatric TB. From 2014 however, Tajikistan will adopt the latest WHO TB definitions and reporting standards that include improved reporting of childhood TB cases.

As in all countries of the region, of major concern is the high rate of MDR-TB infection. A national drug resistance survey conducted in Tajikistan between 2010 and 2011, estimated average MDR-TB rates for new cases at about 13% and about 54% for retreatment cases in the country.

1.2.1 Political commitment to tackle TB in Tajikistan

The Government of Tajikistan (GoT) has acknowledged that TB is a public health threat in the country. It is a signatory to the Berlin and Beijing Declarations on Tuberculosis 2007 and 2009, where it acknowledges that the region has:

“... a high proportion of unfavorable treatment outcomes resulting from poor implementation of internationally accepted TB control strategies and that the use of currently available quality-controlled diagnostics and appropriate evidence-based treatment strategies needs to be further strengthened”.

Nevertheless, the GoT has been taking consistent measures to tackle TB, including:

- The third national programme (2010–2015) to tackle TB effectively is currently being implemented.
- Law on TB care issued in 2006, that includes measures for the social protection of TB patients and TB health care workers.
- In 2012 the Republican TB hospital in Machiton, with support from the German Development Bank, was fully reconstructed and equipped with modern diagnostic instruments. It is now the national centre for TB treatment, lung diseases and TB surgery, hosts the national reference lab and will become a training centre for TB treatment.
- Two regional TB hospitals and a district TB hospital opened recently, all three of which NTP Tajikistan reports as including paediatric TB wards.
A plan of activities including the gradual increase of financing of TB services was drawn up after the President of Tajikistan, Emomali Rahmon, visited the national centre of TB treatment and the Khatlon regional TB hospital.

The Tajikistan national TB programme (NTP) began implementation of MDR-TB treatment in 2009 with support from key partners. However, due to limited resources including a shortage of drugs, children were not considered such a public health priority as they are very often not as infectious as adults and children with drug-resistant TB were not receiving treatment.

Following the commitment to and inception of the MoH/MSF comprehensive paediatric TB programme in 2011, Tajikistan is gradually becoming a forerunner in the systematic diagnosis and treatment of the specialised needs of both DR and drug sensitive (DS) TB in children.

1.3 Paediatric TB Care in Tajikistan

1.3.1 The family TB care programme

To demonstrate the provision of comprehensive TB care for children is feasible, that TB and especially DR-TB can be successfully diagnosed and ultimately cured, the Tajik Ministry of Health and MSF began a comprehensive paediatric TB care programme in 2011.

The family TB care programme aims at improving diagnosis and treatment of DS and DR-TB in children and their families. As children are most likely infected by family members, a holistic treatment approach to the entire family is essential – treating the child alone is redundant. Treatment of adults therefore is crucial to the success of the child’s treatment and it is necessary to treat a household contact if not already in the NTP.

Taking a systematic approach to tackling paediatric TB appropriately, the programme comprises three key components:

1. Early and appropriate diagnosis that includes
   - New diagnostic methods: sputum induction and DST with GeneXpert
   - Contact tracing
   - Scale up of active case finding activities

2. Early and comprehensive treatment
   - Empiric treatment
   - Paediatric drug compounding
   - Systematic monitoring of side effects and their effective management
   - Management of co-morbidities
   - Nutritional support

3. Adherence support for children and their families
   - Psycho-social care for patients and family/caregivers
   - Community- and home-based care
   - An early return to school and provision of education

1.3.2 Programme activities

In total 46 DR paediatric patients are receiving treatment in the country. MSF provides treatment to 39 DR patients, including adult household contacts, 32 of which are MDR-TB and seven XDR-TB infected. The breakdown of the age-groups of DR-TB patients is illustrated below.

Diagram 1: DR-TB cases by age in the MoH/MSF paediatric TB programme as at October 2013.

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 5 years</td>
<td>13%</td>
</tr>
<tr>
<td>5-14 years</td>
<td>23%</td>
</tr>
<tr>
<td>14-18 years</td>
<td>41%</td>
</tr>
<tr>
<td>&gt; 18 years</td>
<td>23%</td>
</tr>
</tbody>
</table>

838 children diagnosed with DS-TB commenced treatment with the NTP in 2011, 599 in 2012 and 568 in 2013. Currently of these DS patients 83 are followed up by MSF.

1.3.3 A new paediatric TB guideline

The 2011 Tajikistan MoH paediatric TB guideline does make reference to MDR-TB. However given the notable differences between children and adult patients, especially in diagnosis with the problem of obtaining biological proof, a new guideline that combines the latest developments and best practice in paediatric DS and DR–TB care was developed by MSF, together with technical input from NTP, WHO and TB partners in Tajikistan.
This guideline is currently combined with the existing 2011 guideline and is undergoing the process for adoption by MoH, including development of the supporting Prikaz (national law). Based on this and together with TB service provider partners, MSF provides training and technical support to MoH medical staff on paediatric DS and DR-TB diagnosis and treatment in the project locations.

2. EARLY AND APPROPRIATE DIAGNOSIS

To prevent the spread of TB and make treatment easier a diagnosis should be made as early as possible. This is why a cornerstone of the family TB programme is the introduction of new diagnostic methods and access to diagnostic services for all TB suspect children in the project areas. Though the process is challenging, children can be confidently diagnosed with a combination of careful analysis of the clinical symptoms and history, contact tracing and tools such as sputum induction and GeneXpert, x-ray and Mantoux test.

2.1 New diagnostic tools: sputum induction and GeneXpert

2.1.1 Sputum induction

The main obstacle to a diagnosis of TB in children is the difficulty of obtaining a specimen for drug sensitivity testing. Even if a good sputum sample can be provided it will be negative in up to 50% of cases as children very often have a low bacillary load. Sputum induction has been shown to be an effective and safe procedure, even in very young children and is safe to use on babies as young as one month old. To maintain the best measures of infection control, the procedure is conducted in a separate sputum induction room away from the patients’ area.

The yield of one induced sputum specimen is comparable to three gastric lavages, but it does not provide the ultimate solution. MoH and MSF continue to search for better methods to obtain specimens from this special patient group, but it is critical that development and trials of other approaches continue.

It is essential that health staff are well trained and skilled to carry out on sputum induction, including proper handling and cleaning of equipment and how to maintain good infection control in the sputum induction room. The risk for the patient is minimal and possible side effects can be managed easily, with the procedure usually performed by trained nurses.

2.1.2 Rapid drug sensitivity testing with GeneXpert

GeneXpert is the crucial diagnostic accompaniment to sputum induction. With sensitivity better than smear microscopy, albeit not as accurate as culture, it has the ability to detect resistance for the most powerful first line drug rifampicin and therefore can indicate MDR-TB. The introduction of GeneXpert has cut the diagnosis time for drug-resistance from a maximum of 42 days to just two hours, making it an essential tool in effective and timely diagnosis and enables to start treatment as early as possible.

For example, having GeneXpert situated in a new biosafety level II lab in the same compound as the hospital and the sputum induction room enabled the project to take a baby of only a few months old through the diagnostic process in a single day.

Furthermore, this supports improved infection control, as it allows for immediate patient segregation and thereby reduces the risk for DS patients of becoming infected with a DR strain. MSF advocates for a DST to be conducted for every child TB suspect if it is possible to obtain sputum.

2.2 Determining the drug resistance pattern through contact history

Given the problems of obtaining biological proof of TB in children, the inclusion of contact tracing in diagnosis is crucial and empiric treatment needs to be considered. Especially in settings with a high DR-TB prevalence, a careful analysis of
contact history is vital and the likely adult source case needs to be identified. It is then virtually certain that the child has the same DST pattern as the index case, since most children with DR-TB have been infected by an infectious adult, and should be treated accordingly.

In the project location in Kulob zone, MSF together with local community nurses and fieldshers from policlinics and rural health posts, have been visiting the patient’s families to determine whether any family members are infected with DS or DR-TB.

2.3 Scaling up active case finding

In the paediatric TB hospital in Dushanbe all patients are screened for DR-TB. However, waiting until patients present to the clinic is insufficient to tackle the scale of the TB problem effectively and active case finding is a way to identify many more (paediatric) TB suspects. In Kulob zone MoH and MSF conducted contact tracing with 20 family households and found 16 TB suspects among 30 under five year old children. Besides screening family households in areas with high TB prevalence, active case finding of TB suspect children should be conducted among population groups that have a high risk of contracting TB such as among street children, in orphanages, schools, HIV clinics or sanatoriums.

MoH Tajikistan is convinced that contact tracing and active case finding needs to be scaled up urgently and should be done systematically at the primary health care level in policlinics and with the involvement of GPs, paediatricians and the extensive network of community nurses and fieldshers in more rural areas of Tajikistan.

Diagram 2: Contact Tracing and Active Case Finding

TB – A family disease

Daler, 7 years old and his brother Abdul, 4 years old, live with their family in a remote mountain village. Daler is infected with MDR-TB, Abdul with a drug-sensitive strain. Their mother, Malika is also infected with MDR-TB. When Malika first was referred to the TB hospital in Dushanbe the NTP conducted contact tracing within the family and found that her two children were also infected, as well as Malika’s sister and her two children. All of them are now enrolled in the MoH/MSF family TB programme and on TB treatment. But TB has taken a toll on the family, seven family members, among them Malika’s brother died undiagnosed and untreated. After a few months in hospital Malika and her children were able to return home and are now continuing their treatment with home-based care. In the family’s village there is no health care post that could provide the directly observed treatment (DOT). Their neighbour Sajodat volunteered to ensure the daily observed drug intake for them, and was trained by the paediatric TB programme to provide care and support to the family. She receives refresher trainings regularly when the project’s nurse and counsellor make monitoring visits. “We visit the family once a month to support them especially in dealing with the often burdensome side effects. We also bring a monthly food parcel for the family to support the treatment and children’s development with additional nutrition”, tells Soro, one of the project’s adherence counsellors.

(All patient’s names are changed in this story.)
2.3.1 Growth assessment

When conducting contact tracing, anthropomorphic indicators – wasting and stunting – are some of the most reliable signs to suspect TB in children along with malnutrition. Growth assessment is also crucial in order to determine if the current TB drug regimen for the child patient is effective – a failure to thrive during treatment indicates a wrong combination of drugs. As a result in the Tajik paediatric TB programme the child’s weight is recorded on a growth chart at every follow up visit to help assess the success of the current TB treatment regimen.

Good nutrition is an integral part of a successful paediatric TB treatment and programme. TB can be a cause of chronic malnutrition, having a negative impact on the future child development. Children with MDR-TB usually require nutritional support. This is being provided in the paediatric TB programme, providing monthly food packages to families in need and therapeutic food to severely malnourished children.
3. EARLY TREATMENT – COMPREHENSIVE CLINICAL MANAGEMENT

Despite the difficulties, when started promptly the outcome of TB treatment in children is generally good, even in those that are young and immune-compromised.21 Children in general tolerate TB drugs well and seem to have fewer side effects than adults, treatment principles are the same as for adults. A regular follow-up of the patient is crucial for a successful cure.

3.1 Paediatric drug compounding

Another area of neglect in childhood TB has been paediatric drug formulations, which are commercially unavailable and no clear guidelines for child friendly compounding of medication have been in place so far. A key challenge remains delivering the exact dosing of the drugs based on the child’s weight. In the Tajik paediatric TB programme a tailored approach with child appropriate drug dosages, compounded according to the children’s weight is applied. Treatment should be individual to every child, with regimens applied as per recommendations in the NTP approved MSF paediatric guidelines.21

In order to obtain tailored doses and formulations MSF has developed a compounding guideline and implemented the compounding of child-friendly syrups from quality controlled and approved second line medication, using a commercially available syrup as a liquid vehicle. The drug compounding is carried out in a commercial pharmacy in Dushanbe according to the drug compounding protocol that has been developed for second and third line drugs. MSF provides second line and side effect drugs for patients in the family TB care project, with patients weighing below 30 Kgs receiving the appropriate drugs as a syrup-formulation.

3.2 Side effect monitoring & management

The debilitating side effects of highly toxic TB drugs are a prime factor impacting on patient adherence to treatment. To support a successful treatment outcome side effects such as nausea, joint pain and deafness need to be managed and there must be systematic monitoring of these in place. It is crucial that the treating doctor or nurse is trained on drug usage, dosage and storage, follow up of the patient and documentation of side effects. MSF provides child-friendly dosages of quality drugs for side effect management to all patients in the project and is implementing a system of side effect management that includes a frequent monitoring and follow up as well as psycho-social support for the patients and their caregivers. In the paediatric TB programme side effect medication is being distributed to policlinics and community nurses involved in the treatment of ambulatory patients.

A severe side effect is hearing loss that can be caused by injectables. It can have an even more disastrous impact for children’s developments than it has in adults as it can influence the ability to learn to speak resulting in the child becoming mute. Hearing loss is more difficult to monitor in children than in adults since they do not necessarily notice hearing loss, so a regular performance of audiometry is a vital component of side effect management.

3.3 TB/HIV co-morbidity

HIV-infected children are extremely vulnerable to develop severe forms of TB following recent exposure and infection.24 If a child suffers from TB/HIV co-morbidity, antiretroviral (ARV) treatment in concert with treatment for the TB infection is a necessity.

It is recommended that for every paediatric TB suspect an HIV test is conducted, voluntary counselling and testing (VCT) offered and the test result disclosed to the patient, caregiver and treating TB doctor. The patient needs to start on ARV treatment, accompanied by HIV adherence support as early as possible meaning good communication and cooperation between TB and HIV services must be in place. In the paediatric TB programme every child is tested for HIV and if the patient is positive, MSF advocates for an ARV treatment therapy intervention. Meanwhile health education about HIV, counselling and adherence support for HIV positive patients and their families is provided alongside the adherence support for TB.

Compounding of a child-friendly syrup from second line TB drugs.
4. SUPPORTING THE CHILD’S DEVELOPMENT - ADHERENCE AND FAMILY SUPPORT

The diagnosis and treatment of TB has a tremendous effect on children. They contract a long term and severe disease in a period of their life of most rapid development. Such seriously ill children suffer detriments to their physical, social and emotional wellbeing in the absence of appropriate support. This is particularly pronounced in a hospital setting, when children may be faced for long periods with minimal stimulation, separation from their families, considerable distance from familiar environments and missing large parts of their schooling.

At the same time, the diagnosis - often heralds a heavy burden for the family, especially an MDR-TB treatment that can last up to two years. This is why a significant component of the paediatric TB programme has been establishing a system of psycho-social support for the child patients and their families that includes assistance through motivational, psychological and social support. Nurses delivering the paediatric TB programme have begun training in basic counselling, child development and behaviour management.

4.1 Psycho-social adherence support for children and their families

The child’s family plays an integral role in supporting their daughter or son in a long and arduous treatment. The central role of the family has been studied for other life threatening and long-term diseases such as cancer.25 Children lack the emotional resources to cope with the disease on their own and rely heavily on practical and emotional support from their caretakers. Any child would struggle with physical and mental shocks that come with a diagnosis and treatment of TB and family members are the greatest potential source of support and strength.26 At the same time parents too struggle with the child’s diagnosis and burdensome treatment and are also in need of support. Therefore in the family TB programme, adherence support counsellors provide regular ongoing support to parents and their children in their best endeavours to adhere to treatment, giving them the best chance of a successful treatment outcome.

These counsellors educate parents on how they can manage the child’s side effects, teach breathing and relaxation techniques, provide education on TB and infection control and make sure the family understands the consequences of a decision not to take TB medication anymore. Adherence counsellors also establish and maintain links between the child and the family when children are hospitalized and help plan a smooth transition from hospital to ambulatory care for the patient.

Mijgona – The first successfully treated MDR-TB patient from the paediatric TB programme

“My daughter was very sick, she lost so much weight and was coughing blood.” Mijgona was one of the first patients enrolled in the family TB programme. “I was diagnosed with TB in policlinic nr. 8”, says Mijgona. “I felt very weak then. The TB drugs helped me a lot, I felt better and better every day.” She was in hospital for four and a half months, and then moved to home based care. In the beginning of the treatment she suffered from various side effects – nausea, headaches, gastric ulcer and her legs and knees hurt a lot. Terry Porshild, Mental Health Officer from the paediatric TB programme, recalls that taking the pills every day over the course of nearly two years was often difficult for Mijgona, but through counselling she was able to endure and keep going. The book of the Tajik poet Rudaki, the counsellors gave me to read helped me a lot. It has a lot of songs in it, stories about life, the motherland, respect for the people – it cheered me up.”

Unfortunately being a household contact infected with MDR-TB, her older brother is also enrolled in the family TB programme. For Mijgona though, the treatment is behind her: “I’m very happy now, I feel very good, I can breathe easily again. I want to learn English now and become a flight attendant or translator”, Mijgona beams as she speaks. She has decided to lend much needed and valuable peer support, speaking about her long struggle but successfully cured disease. At a celebration for her successful treatment at the paediatric TB hospital in Dushanbe, she gave a speech to the other children encouraging them to stick to their challenging treatment.

(Mijgona and her mother gave permission for their real names and photograph to be used.)
4.2 Need for education - return to school and therapeutic play programme

For school-aged children and especially for adolescents it is vital to be close to their peer-group, to be among friends for their wellbeing and to help develop appropriate social skills. School is an important normalizing factor, providing much needed structure, social contacts and the opportunity to gain the necessary skills for life. A study on the importance of education for children with cancer showed that adolescents who returned to school were less socially isolated and happier.27

After having converted to sputum negative, children on TB treatment can go back to school again and should do so in order to maintain contact with their peers and progress in their development. The project’s adherence counsellors motivate children to go back to school and educate school directors that sputum negative children do not create any risk of infection for other children.

Adherence counsellors also provide education and child development stimulating activities in the project’s hospitals. Within the scope of the therapeutic play programme activities such as drawing, reading, handcraft and knitting, health education through stories and plays and ongoing literacy support are offered. For children that are still sputum positive or bed-bound, individual boxes of memory and dexterity enhancing toys and games are supplied. To increase the chance of activities outside, a new playground is being built on the hospital compound of the paediatric TB care hospital in Dushanbe.

I went to school

Seventeen months ago, 16 year old Takhmina was diagnosed with MDR-TB and for eight months she couldn’t go to school. She lives in a small apartment in Dushanbe with her mother, her older sister and her nephew. “When I couldn’t go to school I was very sad and worried a lot. I wanted to study, I like to go to school very much. Shamsia [the project’s adherence support counsellor] helped me a lot during this difficult time.” Shamsia convinced the school director that since Takhmina was not infectious anymore, she should return to school. Every day after school Takhmina goes to the policlinic (health care centre) to get her drugs from a DOT-nurse. She takes 12 drugs every day – they are difficult to swallow, but Takhmina is doing her best. In the afternoon she is tired and usually only has the energy to try to go for a walk in the park, do her homework and watch TV. Nevertheless, Takhmina’s mother stresses that her daughter is doing very well now in class and will sit her final exams this year. For Takhmina, the future holds hope: “After finishing my treatment, I want to become a medical doctor; that has been my dream since childhood.”

(Patient’s name is changed.)

4.3 Relieving children of prolonged hospitalization

Children need to be close to their family - they are the only ones who can truly give them the emotional support they need to cope with the disease. Children with TB are presently hospitalized for many months, away from their families and without the possibility to go to school or kindergarten. Experiences from the paediatric TB programme show that parents usually lack the resources to be close to their children in hospital. As they do not possess the emotional resources of adults, separation from family members in particular can provoke anxiety in a child28 and especially for a protracted disease such as DR-TB, therefore, a return to home and commencement of ambulatory care as early as possible is preferable.

Moreover staying in a hospital environment without proper infection control creates the risk for cross-infection with different strains of TB. With a lack of drug sensitivity testing before admission and the attendant separation of patients, hospitalization is a notable risk factor for acquiring MDR-TB. In addition ambulatory care also helps reduce the pressure on hospitals capacity where there are no MDR-TB wards.
5. CONCLUSIONS AND RECOMMENDATIONS

The experience from the Family TB Care Programme has shown that provision of high quality DR and DS-TB diagnosis and treatment for children is feasible in Tajikistan and therefore potentially in other countries in the region. To treat childhood TB effectively, a comprehensive treatment model for the whole family is needed.

The learnings of this programme experience suggest the following three key recommendations:

1. Early and appropriate diagnosis

   • To prevent the spreading of TB and make treatment easier, childhood TB needs to be diagnosed appropriately as early as possible. Biological proof is the ideal indicator and should be sought, so every TB suspected child should have access to a good DST. The new diagnostic tools of sputum induction and GeneXpert have added much capability to this process, but there is still a long way to go to resolve the challenges of diagnosing TB in children.
   • If it is not possible to obtain biological proof, empiric treatment and contact tracing must be employed.
   • Scale up of active case finding activities: A proper case finding strategy at policlinic level should be put in place. The cohort of children currently on TB treatment needs to be reviewed and DS testing undergone in all cases. In case of diagnosis with DR TB, patients need to be transferred to the DR-TB treatment regimen.

2. Early and comprehensive treatment

   • Paediatric drug compounding: In order to obtain child friendly, tailored doses and formulations the compounding of paediatric drug TB drug formulations is recommended.
   • Side effect monitoring and management: To improve adherence, free of charge side effect drugs need to be provided to the patients and a systematic approach to monitoring of patient’s symptoms and treatment progress needs to be implemented.
   • TB/HIV co-infection: For every TB suspect an HIV test needs to be conducted, VCT offered and the test result disclosed to the patient, parents and treating TB doctor. The patient needs to commence ARV treatment, accompanied by HIV adherence support. Good communication and cooperation between TB and HIV services must exist.
   • Nutritional support should be included in paediatric TB care, especially for DR-TB infected children.

3. Appropriate patient and family support

   • Psycho-social care for patients and family/caregivers: A system of psycho-social adherence support should be put in place with (DOT-)nurses trained to provide adherence support.
   • Community-based care and schooling: A prolonged hospitalization needs to be avoided and ambulatory treatment as early as possible favored in order to avoid negative impact on the child’s development. Non-infectious children should go back to school again so that they can continue their education.

Children cannot be neglected in the treatment of TB. Since paediatric TB is an indicator for the current control of TB in the general population, and also acts as a future reservoir for TB disease, new approaches to paediatric TB care should be integrated into every TB project and National TB programme. MoH Tajikistan and MSF have made significant progress towards recognizing and addressing the multifaceted challenges that childhood TB presents. The experiences to date have provided a rich source of learnings about what works and what needs much more investment and effort to get right. Together however MoH, MSF and TB partners in Tajikistan will continue to search for and develop better solutions to diagnose and treat TB in children.
References

1 In the MSF Paediatric TB Programme children are patients below the age of 18 years. WHO figures for paediatric TB comprise children below the age of 15 years.


14 According to data from Gauting Supranational Reference Laboratory and Project Hope, National Drug Resistance Survey Tajikistan 2012, Presented at the Round Table on the DR Survey Tajikistan 2012, Dushanbe.


16 Law of the Republic of Tajikistan on Tuberculosis from 22 December 2006, Nr. 223.

17 National TB Programme Tajikistan 2013, unpublished figures.

18 National TB Programme Tajikistan 2013, unpublished figures.


List of abbreviations

ARV – antiretroviral

DOT – Directly Observed Treatment

DR-TB – drug resistant tuberculosis

DS-TB – drug sensitive tuberculosis

DST – drug susceptibility testing

GoT – Government of Tajikistan

HIV – Human immunodeficiency virus

MDR-TB – multidrug resistant tuberculosis

MoH – Ministry of Health

MSF – Medics Sans Frontieres

NTP – National Tuberculosis Programme

TB – tuberculosis

VCT – Voluntary Counselling and Testing

WHO – World Health Organisation

XDR-TB – extensively drug resistant tuberculosis
MSF’s current projects in Central Asia and Eastern Europe:

Armenia
MSF began supporting the Armenian health authorities in 2005 in response to the drug-resistant TB (DR-TB) epidemic in the country. As of 2013, more than 1000 DR-TB patients have been treated. Through MSF support the detection, diagnosis and treatment of DR-TB has improved significantly. MSF is also supporting DR-TB care in the Republic of Nagorno-Karabagh and started supporting the National TB programme (NTP) to introduce three new drugs for extensively drug-resistant TB (XDR-TB) treatment. One of the drugs was introduced through a compassionate use programme, which is potentially lifesaving for individual patients left with no other treatment option.

Russian Federation
MSF has been working in the Russian Federation since the early 1990s. Over the years, MSF has run programmes in Moscow, Saint Petersburg, the Kemerovo region, Chechnya, Ingushetia and Dagestan – today the organization is still active in Chechnya. Together with the Chechen Ministry of Health, MSF has rebuilt the republic’s system for laboratory diagnostics, set up DOT-corners throughout the republic, established infection control measures in TB facilities and organised a system for providing psychosocial and adherence support for patients. MSF strongly promotes ambulatory care from day one for the treatment of TB in Chechnya. In addition to a GeneXpert machine, the lab in Grozny is equipped with a BACTEC machine, enabling it to conduct a DST for first line drugs within two weeks; samples for second line DST are routinely referred to the Central TB Research Institute lab in Moscow.

Georgia/Abkhazia
MSF has been working in Georgia and the autonomous republic of Abkhazia since 1999 to support the local health authorities in tackling the TB public health crisis. In 2013, MSF in collaboration with the Georgian NTP is preparing a clinical trial for new anti-TB drugs. In Abkhazia, MSF continues to provide essential support for the fight against DR-TB while gradually handing over its activities to the local health authorities until July 2014.

Kyrgyzstan
A recent MSF paper reports that the incidence of TB among prisoners in Kyrgyzstan is estimated to be 20 to 30 times higher than among the general population and mortality rates can be up to 60 times higher. Working in collaboration with the MoH, the prison authorities and the International Committee of the Red Cross, MSF began providing TB care in detention centres in 2006. In addition, MSF opened a project in the civilian sector in the Kara–Suu district of Osh in 2012. This project is currently treating 142 patients with MDR- and XDR-TB, nearly 80 percent of whom are treated on an ambulatory basis.

Tajikistan
In 2011, MSF and the MoH in Tajikistan started a paediatric TB programme to address the global neglect in paediatric TB care and improve diagnostics and treatment of TB in children in the country and beyond. In this holistic approach, children as well as their family members are being treated. The programme promotes the use of sputum induction, a rapid DST for every child with suspected TB, the scale up of contact tracing activities and paediatric drug compounding.

Ukraine
TB, including drug-resistant TB, is one of the major public health problems in Ukraine today. Prisoners and ex-prisoners are considered particularly vulnerable groups, with many having a history of injecting drug use and a consequently higher risk of HIV infection. The reported levels of TB–HIV co-infection among prisoners and the high risk of DR-TB have led MSF to work in the country’s penitentiary system, where the provision of services for DR-TB care is limited. In January 2011, in partnership with the Ukrainian MoH and the State Penitentiary Department of Ukraine, MSF opened a new project in Donetsk.

Uzbekistan
In Karakalpakstan, an autonomous republic in Uzbekistan’s north, MSF in close collaboration with the MoH Uzbekistan and MoH Karakalpakstan has rolled out treatment for TB in a number of districts in response to a high DR-TB prevalence in the area. MSF is currently working in ten rayons (districts) of Karakalpakstan, diagnosing and treating patients with drug sensitive (DS) TB and DR-TB. By the end of August 2013, a total of 865 DR-TB patients and 768 DS patients were receiving treatment in the joint MoH/MSF programme and recently a new nine months treatment regimen commenced in two of the rayons. MSF together with the MoH have started working together in the national HIV programme to improve diagnosis and treatment of HIV in the country.